<DOC>
	<DOCNO>NCT00877604</DOCNO>
	<brief_summary>The preclinical rationale tauroursodeoxycholic acid ( TUDCA ) use treat patient amyotrophic lateral sclerosis ( ALS ) stem demonstration antioxidant , antiapoptotic neuroprotective property TUDCA central nervous system ( CNS ) , vitro vivo model . This protocol mean assess addition TUDCA conventional therapy improve therapeutic outcome patient affected ALS . Safety assess subject , entire duration study . 30 patient affected ALS site onset limb recruit . All enrolled subject continue receive riluzole regimen enter trial . Based appropriate random code , subject divide two group equal size treat , lead-in period 3 month , oral route TUDCA dose 2 g daily 1 year identical placebo oral route dosing schedule , double-blind condition . Every concomitant and/or supportive therapy admit . Evaluation criterion : Efficacy . The proportion responder patient two treatment group primary outcome measure study . Responder patient define subject show improvement least 15 % ALSFRS-R ( 2 ) slope treatment period compare lead-in period . This threshold chosen base accord consensus conference design implement clinical trial ALS ( 3 ) . Other parameter include ALSFRS-R study end , FVC % , SF-36 quality life rating scale , time tracheotomy start study medication dosing ( appropriate ) , survival Time start study medication dosing ( appropriate ) , Medical Research Council score right leave muscle group . Safety . Incidence , severity type adverse event ; change clinical laboratory finding .</brief_summary>
	<brief_title>Efficacy Tolerability Tauroursodeoxycholic Acid Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis ( ALS ) , motor neuron disease ( MND ) , rapidly progressive , fatal neurodegenerative condition characterize loss upper low motor neuron brain spinal cord . The term ALS MND often use inter-changeably cover different clinical syndrome , include upper low motor neuron disorder , progressive bulbar palsy , pseudo-polyneuritic form . Degeneration low motor neuron ( LMN ) anterior horn spinal cord brainstem lead progressive muscular atrophy eventually death within year due respiratory insufficiency . During course disease , involvement tongue pharynx muscle cause swallow impairment mark drooling , need parenteral enteral feeding , finally gastrostomy . Denervation laryngeal muscle cause loss speech . Cramps fasciculation typically occur early phase disease . Degeneration upper motor neuron ( UMN ) brain cortex cause pyramidal tract dysfunction include clonus , Babinski sign , hypertonia , loss dexterity limit patient ' daily activity . The incidence ALS vary 0.2 2.5 case per 100,000 per year , although estimate vary country , likely reflect combination availability medical service , diagnostic accuracy , demo-graphic characteristic area . Increasing life expectancy improvement standard treatment care also result increase incidence ALS . Globally , overall rate approximately 2 per 100,000 . Its prevalence approximately 7 per 100,000 . In Italy , report incidence ALS 2.2 cases/100,000/year . There currently cure ALS . Despite initial positive result preclinical early clinical study , large-scale clinical trial agent except riluzole fail demonstrate clinically meaningful therapeutic effect patient ALS . Riluzole dose 100 mg/day show significant difference survival ( 6.4 % ; gain 3 month ) slow deterioration muscle strength . Primary involvement apoptotic mechanism important implication select drug candidate therapy ALS . Recent preclinical study demonstrate TUCA endow antioxidant , antiapoptotic neuroprotective activity . In particular , TUDCA cross blood-brain-barrier show exert significant therapeutic effect model HD mouse . Tauroursodeoxycholic acid ( TUDCA ) hydrophilic bile acid normally produce endogenously human low level . TUDCA synthesize liver conjugation taurine ursodeoxycholic acid ( UDCA ) , commonly use bile acid replacement therapy treatment certain cholestatic syndrome . The main pharmacological activity TUDCA consist ability increase cholesterol solubilising activity bile , thus transform `` lithogenic '' bile `` non-lithogenic '' `` litholytic '' bile . TUDCA inhibit mitochondrial-associated apoptosis via many pathway : 1 ) inhibit mitochondrial permeability transition ( MPT ) cytochrome C release , 2 ) inhibit mitochondrial membrane depolarization , 3 ) antagonize Bax translocation mitochondrion caspase activation hepatocytes brain . TUDCA may also ease oxidative stress.Study relevant TUDCA pharmacology consist antioxidant , antiapoptotic neuroprotective activity evidence preclinical study . Recent report show hydrophilic bile acid , UDCA TUDCA , prevent hepatic cytotoxicity several mechanism . For example , TUDCA prevent production reactive oxygen specie thus act antioxidant . Additionally , TUDCA mitigate mitochondrial insufficiency toxicity , prevents apoptosis , part , inhibit Bax translocation cytosol mitochondrion . In hepatocytes , inhibition result reduce mitochondrial membrane perturbation , release cytochrome c , activation downstream caspase . TUDCA reduce cytotoxicity neuron similar mechanism , well mitochondrial pathway independent permeability transition . TUDCA prevent striatal degeneration ameliorate locomotor cognitive deficit vivo 3-nitropropionic acid ( 3-NP ) rat model HD . Intracellular inclusion significantly reduce , TUDCA-treated mouse show improved locomotor sensorimotor ability . In addition , antiapoptotic cytoprotective effect TUDCA test model acute stroke . The possibility TUDCA exert antiapoptotic action ameliorate mitochondrial function raise issue whether neurological disorder , include Friedreich 's ataxia , amyotrophic lateral sclerosis , Parkinson 's disease , Alzheimer 's disease , benefit administration TUDCA . This drug candidate neuroprotective agent variety chronic neurodegenerative condition .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Tauroursodeoxycholic acid</mesh_term>
	<mesh_term>Taurochenodeoxycholic Acid</mesh_term>
	<criteria>Caucasian male female outpatient ; age 18 75 year inclusive ; diagnosis `` probable '' `` definite '' amyotrophic lateral sclerosis accord El Escorial revise criterion ( 1 ) ; first symptom ALS 1.5 year ; treatment steady regimen riluzole minimum 3 month study entry , desire continuation ; FVC â‰¥ 75 % predict ; condition know contraindication use TUDCA ; write informed consent . subject underwent tracheostomy ; subject underwent resection gall bladder ; subject sign conduction block motor nerve , sensory nerve nerve conduction study ; subject clinical sign dementia ; subject active peptic ulcer ; subject active malignancy ; subject bulbar onset ; female subject pregnant lactating subject receive experimental drug participate clinical trial within 3 month prior screen employee investigator study centre direct involvement propose study study direction investigator study centre .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>ALS</keyword>
	<keyword>Therapy</keyword>
	<keyword>Tauroursodeoxycholic acid</keyword>
	<keyword>TUDCA</keyword>
	<keyword>antioxidant</keyword>
	<keyword>antiapoptotic drug</keyword>
	<keyword>neuroprotective drug</keyword>
</DOC>